All In Biotech

Drug Trial Radar · NCT04147195

Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)

NASH EXploratory Single and COmbination Treatment (NEXSCOT): An Open Label, Multicenter, Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Various Single and Combination Treatments in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) Who Manifest a Non-alcoholic Steatohepatitis (NASH)-Like Biomarker Phenotype

Last checked: Nov 19, 2026Latest source record: Aug 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

41

Actual

Start

Jun 4, 2020

Primary completion

Jan 6, 2022

Study completion Jan 6, 2022

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study was designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of various single and combination treatments in adult patients with non-alcoholic fatty liver disease (NAFLD) who manifest a non-alcoholic steatohepatitis (NASH)-like biomarker phenotype.

Conditions

  • Non-alcoholic Fatty Liver Disease
  • Nonalcoholic Steatohepatitis

Interventions

  • LYS006Drug

    5 mg LYS006 capsules orally administered 20 mg b.i.d for 12 weeks

  • TropifexorDrug

    100 ug LJN452 capsules orally administered 200ug once daily for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From the start of treatment to 28 days after end of treatment, assessed up to maximum duration of 113 Days

Locations

10 sites in 3 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Coronado, California

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Miami Lakes, Florida

  • Novartis Investigative Site

    Marietta, Georgia

  • Novartis Investigative Site

    Honolulu, Hawaii

  • Novartis Investigative Site

    South Bend, Indiana

  • Novartis Investigative Site

    Morehead City, North Carolina

  • Novartis Investigative Site

    San Antonio, Texas

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Essen, Nordrhine Westphalia, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.